Trastuzumab duocarmazine

Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas. Trastuzumab duocarmazine has a Drug-to-antibody ratio (DAR) of 4.0, it's molecular weight is 145kDa. This product is for research use only.

Product Details
Species Reactivity	Human
Type	Antibody-drug conjugate
ADC antibody	Trastuzumab (anti-HER2)
ADC cytotoxin (drug)	MMAE
Immunogen	Human HER2
DAR (Drug to Antibody Ratio)	2.8
Purity	99%
Molecular Weight	145KDa
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	1xPBS